Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era

Erdheim-Chester disease (ECD) is a rare histiocytosis that was recently recognized as a neoplastic disorder owing to the discovery of recurrent activating MAPK (RAS-RAF-MEK-ERK) pathway mutations. Typical findings of ECD include central diabetes insipidus, restrictive pericarditis, perinephric fibro...

Full description

Saved in:

Bibliographic Details
Published in:	Blood Vol. 135; no. 22; p. 1929
Main Authors:	Goyal, Gaurav, Heaney, Mark L, Collin, Matthew, Cohen-Aubart, Fleur, Vaglio, Augusto, Durham, Benjamin H, Hershkovitz-Rokah, Oshrat, Girschikofsky, Michael, Jacobsen, Eric D, Toyama, Kazuhiro, Goodman, Aaron M, Hendrie, Paul, Cao, Xin-Xin, Estrada-Veras, Juvianee I, Shpilberg, Ofer, Abdo, André, Kurokawa, Mineo, Dagna, Lorenzo, McClain, Kenneth L, Mazor, Roei D, Picarsic, Jennifer, Janku, Filip, Go, Ronald S, Haroche, Julien, Diamond, Eli L
Format:	Journal Article
Language:	English
Published:	United States 28.05.2020
Subjects:	Clinical Trials as Topic Erdheim-Chester Disease - diagnosis Erdheim-Chester Disease - genetics Erdheim-Chester Disease - therapy Female Histiocytosis, Langerhans-Cell - diagnosis Histiocytosis, Langerhans-Cell - genetics Histiocytosis, Langerhans-Cell - therapy Humans Male MAP Kinase Signaling System - drug effects MAP Kinase Signaling System - genetics Molecular Targeted Therapy Mutation Prognosis Proto-Oncogene Proteins B-raf - antagonists & inhibitors Proto-Oncogene Proteins B-raf - genetics
ISSN:	1528-0020, 1528-0020
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!